Stock price fluctuation, Zhaoyan New Drug states that there is no major information that should be disclosed but has not been disclosed.

NightAirdropper · 2026-03-31T14:13:02+00:00

Zhaoyan New Drug announced on March 31 that the company's stock price increased by more than 20% over three consecutive days on March 27, 30, and 31, which is considered an abnormal fluctuation. The company confirmed that there are no undisclosed major information and reminded investors to be aware of trading risks.

NightAirdropper

2026-03-31 14:13:02

Abstract generation in progress

Beijing Business Today, reported by (Ding Ning) On the evening of March 31, Zhaoyan New Drug (603127) released a notice regarding abnormal stock price fluctuations, which shows that the company’s stock closed with an accumulated price increase deviation value of more than 20% over three consecutive trading days on March 27, March 30, and March 31. According to the relevant provisions of the Shanghai Stock Exchange’s Trading Rules, this falls under circumstances of abnormal stock trading price fluctuations.

Zhaoyan New Drug states that, after the company conducted a self-check and formally consulted its controlling shareholder and actual controller in writing, as of the date of disclosure of the announcement, the company and its controlling shareholder and actual controller confirm that there is no major information that should have been disclosed but has not been disclosed. The company’s stock price has risen significantly in the short term. Investors are kindly reminded to pay attention to risks in secondary-market trading, make rational decisions, and invest prudently.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes